We recently compiled a list of the 10 Companies Jump on Better Earnings, Outlook. In this article, we are going to take a ...

Hundreds of thousands of doses of moxidectin – which treats a disease caused by a parasitic worm – are being given to ...

We recently compiled a list of the 10 ... Last year, GSK reported nearly halving its net profit after settling hefty US lawsuits over its Zantac heartburn drug. Net income after tax dropped ...

The list for the next round of medicines that will ... reckons a chronic obstructive pulmonary disease (COPD) drug will be included – and is preparing to contribute to the process.

Democrats sought answers from RFK Jr. on how the Trump administration would handle Medicare price negotiations after a short ...

Astellas Pharma’s prostate cancer drug, Xtandi, is also on the list — alongside AstraZeneca’s cancer treatment Calquence, GSK’s chronic obstructive pulmonary disorder (COPD) drug Breo Ellipta, and ...

The table below is a review of notable updates that occurred in January 2025 for investigational products in development.

The list of 15 medicines includes blockbuster drugs from Novo Nordisk, Pfizer, Bristol Myers Squibb, AstraZeneca, GSK and other companies. Novo’s booming semaglutide franchise for diabetes and ...

The next costliest was GSK's asthma and chronic obstructive ... That law requires Medicare to essentially make a list of eligible drugs for the program, and then select the drugs that make up ...

Select listed pharma player including Pfizer, Novartis India, AstraZeneca Pharma and GSK Pharma shall be the beneficiaries of ...

We recently compiled a list of the 12 ... GSK plc (NYSE:GSK) is advancing several promising assets in oncology and respiratory, including B7-H3 and B7-H4 antibody-drug conjugates for difficult ...

The selected drug list for the second cycle of negotiations ... Ibrance for breast cancer and Xtandi for prostate cancer. GSK Plc's (NYSE:GSK) Asthma and Chronic obstructive pulmonary disease ...